Effect of Metformin on Lipid profile of type II Diabetes

Garimella, Sumanth; Seshayamma, V; Rao, Hari Jagannadha; Kumar, Siva; Kumar, Upendra; Saheb, Shaik Hussain

doi:10.16965/ijims.2016.155

Cited by 12 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the mechanism of metformin is still unclear at the molecular level, fortunately, a wealth of recent studies have determined that metformin provides a glucose‐lowering effect inhibiting hepatic gluconeogenesis, via activating 5′ AMP‐activated protein kinase (AMPK)‐ one of the prominent metabolic sensors of the cell . AMPK also mediates the downregulation of the fatty acid synthesis pathway, the mechanistic target of rapamycin (mTOR) and acetyl‐CoA‐carboxylase partially . Metformin exposure induces mTOR signalling, downregulation of insulin‐like growth factor 1 and hyperinsulinaemia, thereby influencing proliferation, autophagy, and cell growth .…”

Section: Effects Of Metformin On Ageingmentioning

confidence: 99%

“…50 AMPK also mediates the downregulation of the fatty acid synthesis pathway, the mechanistic target of rapamycin (mTOR) and acetyl-CoA-carboxylase partially. 51 Metformin exposure induces mTOR signalling, downregulation of insulin-like growth factor 1 and hyperinsulinaemia, thereby influencing proliferation, autophagy, and cell growth. 52 Along with downregulation pro-inflammatory NF-kB signalling, enhanced insulin sensitivity in parallel with reduced hyperglycaemia results in minimized formation of ROS and AGE.…”

Section: Effec Ts Of Me Tformin On Ag Eingmentioning

confidence: 99%

See 1 more Smart Citation

NF‐κB as the mediator of metformin's effect on ageing and ageing‐related diseases

Sultuybek

Soydaş

Yenmiş

2019

Clin Exp Pharma Physio

102

View full text Add to dashboard Cite

Summary Ageing can be defined as the progressive failure of repair and maintenance systems with a consequent accumulation of cellular damage in nucleic acids, proteins, and lipids. These various types of damage promote ageing by driving cellular senescence and apoptosis. The nuclear factor‐kappa B (NF‐kB) pathway is one of the key mediators of ageing and this pathway is activated by genotoxic, oxidative and inflammatory stress, and regulates expression of cytokines, growth factors, and genes that regulate apoptosis, cell‐cycle progression, and inflammation. Therefore, NF‐kB is increased in a variety of tissues with ageing, thus the inhibition of NF‐kB leads to delayed onset of ageing‐related symptoms and pathologies such as diabetes, atherosclerosis, and cancer. Metformin is often used as an anti‐diabetic medication in type 2 diabetes throughout the world and appears to be a potential anti‐ageing agent. Owing to its antioxidant, anticancer, cardio‐protective and anti‐inflammatory properties, metformin has become a potential candidate drug, improving in the context of ageing and ageing‐related diseases. An inappropriate NF‐kB activation is associated with diseases and pathologic conditions which can impair the activity of genes involved in cell senescence, apoptosis, immunity, and inflammation. Metformin, inhibiting the expression of NF‐kB gene, eliminates the susceptibility to common diseases. This review underlines the pleiotropic effects of metformin in ageing and different ageing‐related diseases and attributes its effects to the modulation of NF‐kB.

show abstract

Section: Effects Of Metformin On Ageingmentioning

confidence: 99%

Section: Effec Ts Of Me Tformin On Ag Eingmentioning

confidence: 99%

NF‐κB as the mediator of metformin's effect on ageing and ageing‐related diseases

Sultuybek

Soydaş

Yenmiş

2019

Clin Exp Pharma Physio

102

View full text Add to dashboard Cite

show abstract

“…Garimella S. et al [14] had revealed significant (p<0.05) reduction in triglycerides. The results were clearly indicated that beneficial effect of Metformin on lipid profile of type II diabetes.…”

Section: Resultsmentioning

confidence: 88%

A CROSS SECTIONAL STUDY IN NORTH EASTERN UTTAR PRADESH POPULATION FOR THE ESTIMATION OF BMI, HDL & TRIGLYCERIDES LEVELS IN RECENTLY DIAGNOSED PATIENTS WITH TYPE 2 DIABETES MELLITUS TAKING METFORMIN ALONE, METFORMIN WITH ADD ON SITAGLIPTIN AND SITAGLIPTIN ALONE.

Neerjesh¹

2017

WJPR

View full text Add to dashboard Cite

show abstract

“…A review on metformin by Goley showed that effect of metformin on body weight in various randomized controlled trials was variable, with about half of studies demonstrating significant reductions in body weight with metformin, relative to baseline or comparator [14]. [17]. Improvement in beta cell function (HOMA-β) and insulin resistance (HOMA-IR) was significant suggesting the role of metformin as insulin sensitizer.…”

Section: Discussionmentioning

confidence: 99%

Effect of Lifestyle Modification and Oral Anti-Diabetic Drugs on Metabolic Parameters in Recently Diagnosed Patientswith Uncomplicated Type 2 Diabetes Mellitus in Eastern India

Pradhan¹,

Das²,

Parhi³

et al. 2018

JDM

View full text Add to dashboard Cite

BACKGROUND: Oral anti-diabetic drugs (OADs) are often advised for initial treatment for patients with Type 2 Diabetes Mellitus (T2DM). Their effects on glycemic control, lipid profile, insulin resistance and beta cell function has not been systematically studied in India. The objective of this study was to evaluate the effect of lifestyle modification and OADs on metabolic parameters in recently diagnosed uncomplicated T2DM patients. MATERIAL METHODS: A total of consecutive sixty four (64) cases of recently diagnosed uncomplicated T2DM in the age group of 30 -60 years were studied. They were evaluated for weight, body mass index (BMI), fasting plasma glucose (FPG), 2hr post glucose plasma glucose (2hrPGPG), HbA1c, lipid profile, serum fasting insulin, c-peptide, HOMA-IR and HOMA-β. They were divided into four groups according to increasing order of HbA1c values (6.5% -6.9%, 7% -7.5%, 7.6% -8.5%, 8.6% -8.9%). These four groups were subjected to lifestyle modification (LSM), monotherapy with metformin (1 g) and LSM, dual drug therapy i.e. metformin (1 g), glimepiride (1 mg) and LSM, triple drug therapy i.e. metformin (1 g), glimepiride 1 mg, sitagliptin 100 mg) and LSM respectively. These patients were followed up after three months of therapy. They were evaluated for the same metabolic parameters and compared with their baseline value. Fourteen (14) patients were lost to follow up. RESULTS: We found 91%, 92.8%, 53.3% and 60% of our patients from above four different groups achieved target glycemic control (HbA1c ≤ 6.5%). In all

show abstract

Effect of Metformin on Lipid profile of type II Diabetes

Cited by 12 publications

References 18 publications

NF‐κB as the mediator of metformin's effect on ageing and ageing‐related diseases

NF‐κB as the mediator of metformin's effect on ageing and ageing‐related diseases

A CROSS SECTIONAL STUDY IN NORTH EASTERN UTTAR PRADESH POPULATION FOR THE ESTIMATION OF BMI, HDL & TRIGLYCERIDES LEVELS IN RECENTLY DIAGNOSED PATIENTS WITH TYPE 2 DIABETES MELLITUS TAKING METFORMIN ALONE, METFORMIN WITH ADD ON SITAGLIPTIN AND SITAGLIPTIN ALONE.

Effect of Lifestyle Modification and Oral Anti-Diabetic Drugs on Metabolic Parameters in Recently Diagnosed Patientswith Uncomplicated Type 2 Diabetes Mellitus in Eastern India

Contact Info

Product

Resources

About